Luca Licata: The fate of immunotherapy trials in breast cancer
Marco Mariani, Resident in Medical Oncology at San Raffaele Scientific Institute, shared a post on X about a recent paper titled “Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.” published on JAMA Network Open.
Authors: Marco Mariani, Giulia Viale, Barbara Galbardi, Luca Licata, Carlo Bosi, Matteo Dugo, Giulia Notini, Matteo M. Naldini, Maurizio Callari, Carmen Criscitiello, Lajos Pusztai, Giampaolo Bianchini.
“Excited to share our latest publication on JAMA Network Open: ‘Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.’
Check out some key insights below.
Our study analyzed 331 immuno-oncology breast cancer trials initiated by April 2023. Despite the high number of trials, only Pembrolizumab, is approved under two indications (plus Atezolizumab in EU). What happened?
Exploring PD-1 and PD-L1 combination strategies revealed a broader application beyond triple-negative breast cancer (TNBC).
Among trials with primary completion dates up to November 30, 2022, a notable 25% remain unreported. Single-center studies were significantly more likely to be unreported. Furthermore, only 2 out of 19 randomized trials yielded positive results.
Despite the large number of trials, the clinical impact has been modest. This suggests the need for a more selective initiation of phase II trials, grounded in preclinical and biomarker observations, with optimal statistical designs for early efficacy assessment.
I truly fell blessed for the support of our incredible team and the guidance of my mentors Giampaolo Bianchini and Lajos Pusztai.”
Luca Licata, Medical Oncologist at San Raffaele Scientific Institute, shared the post by Marco Mariani, adding:
“Just out on JAMA Network Open our study on the fate of immunotherapy trials in breast cancer, led by Marco Mariani.
Take a look at the terrific job and excellent tweetorial he did.”
Source: Marco Mariani/X and Luca Licata/X
